Tue, Jul 22, 2014, 6:51 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Affymax, Inc. (AFFY) Message Board

  • affy_fly affy_fly Jun 15, 2013 10:31 AM Flag

    to godwinpeak: where does your statistics come from

    Where does your statistics come from? Could you list the reference? I am very interested and curious. They are very important to my decision.

    your statistics:

    Sudden death - 2.1% O, 0.3% Epo [O has 7x higher incidence]
    Death from unknown cause- 2.4% O, 1.2% Epo [O has 2x higher incidence]
    Unstable angina - 2.4% O, 0.9% Epo [O has 2.6x higher incidence]
    Arrythmia - 5.6% O, 4.0% Epo [O has 1.4x higher incidence]
    Acute Renal Failure - 8.5% O, 4.3% Epo [O has 2x higher incidence]
    Convulsions - 1.2% O, 0.3% [O has 4x higher incidence]
    Treatment Failure - 3.5% O, 1.5% Epo [O has 2.3x higher incidence]

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • See J. Glever, Omontys Safety Still a Problem for Nondialysis Patients, MedPage Today (Jan. 23, 2013).

      • 1 Reply to godwinpeak
      • godwinpeak, I went through your listed reference and related original NEJM articles for the reference. Either you are literally inferior or intentionally misleading people, I have to pointed out that: your statistics are for NON-dialysis Patients (from studies PEARL-1 and PEARL-2). Actually the studies for dialysis Patients are labeled EMERALD 1 and 2.

        Before the approval, the elevated cadiovascular risk on non-dialysis patients is a topic of discussion at the FDA advisory committee meeting, so FDA fully aware of the issue. FDA approves Omontys to only treat anemia in adult patients on dialysis, not non-dialysis Patients. Since the drug is for dialysis patient, godwinpeak, you should list the statistics for dialysis Patients, but you can't: Omontys is as good as Epogen, and only need to be administered once a month.
        In fact, not just YMB, godwinpeak intentionally post such misleading statistics on SeekingAlpha too. I have to say: godwinpeak, you are low.

        Further, I smelly fishy with the reference article itself. The article used title "Omontys Safety Still a Problem for Nondialysis Patients", but strongly emphasize that: in an accompanying NEJM editorial article, the author "suggested that there may not be a compelling reason to prescribe peginesatide for ANY patient regardless of dialysis status". Please read the editorial article yourself, everyone. People can find that the author did not provide such allegation at all. What the author wrote down is: "Peginesatide can be used for anemia correction in patients undergoing hemodialysis, in which case its efficacy profile is similar to the profiles of established ESAs, but concerns remain about its safety in patients not receiving hemodialysis."

        Tinted internet article pass around. Totally misleading statistics posted everywhere. Cann't all these be a planned plot of the competitor?

        Conclusion:
        Omontys is approved for dialysis patients. Omontys' efficacy is similar to Epogen on dialysis patients.

    • gadflypeak stats get pulled from his aess which is where his head resides! Lolololol

    • I am certain I answered this question...Stats are verifiably fraudulent since there were ZERO DEATH FROM OMONTYS DURING THE CLINICAL TRIALS...So how on earth could EPO have better mortality stats than Omontys if this was (as it was stated) clinical trial data. Post FDA approval the fatality % for Omontys was .02% (5 fatalities out of 25000, with two of those already known as unrelated to Omontys and the rest in the results of investigation)...So even if you took POST FDA Approval those relative stats are bogus. TO DO MORE RESEARCH ON THIS GOOGLE THE FOLLOWING:
      EPOGEN FATALITIES
      EPOGEN DEATHS
      AMGEN FATALITIES
      AMGEN DEATHS
      FRESENIUS FATALITIES
      FRESENIUS DEATHS
      AND ALL OF THE ABOVE COMPANIES ADD THE WORDS SAFETY RISKS to your various searches.

      OF COURSE MOST OF US HAVE DONE THE SAME RESEARCH USING OMONTYS AND AFFYMAX DEATHS, FATALITIES AND SAFETY RISKS. Easiest place to get original info is Takeda's website then click on top right "search" and put in either Affymax or Omontys...Omontys will give you the complete chronology of events and stats !!!

      • 2 Replies to maxdad01
      • Thanks a lot for all of your great work, maxdad1. Appreciate it.

      • Another deceitful post from Judas Sheep Maxdad. I have already called him out for several outright deceptions or lies if one wants to be blunt. Some lies are even knowingly and purposefully made by Maxdad as, for example, when he posted that Takeda had given Affymax $10M in working capital. With Maxdad a proven GS/JPM fraudster, it is astonishing to me that anyone would take him seriously. It is my opinion that Maxdad may employ/oversee a group of paid pumpers who laud and hang on his every word to make it appear that he is someone credible instead of what he actually is - a Judas Sheep. Since O did have deaths in clinical trials, is Maxdad lying once again or is he just mistaken or will he not answer again or just launch another personal attack against me for showing the truth? To prove my point, here are the results of the EMERALD studies that include O deaths among other serious adverse patient reactions:

        Sudden death - 2.1% O, 0.3% Epo [O has 7x higher incidence]
        Death from unknown cause- 2.4% O, 1.2% Epo [O has 2x higher incidence]
        Unstable angina - 2.4% O, 0.9% Epo [O has 2.6x higher incidence]
        Arrythmia - 5.6% O, 4.0% Epo [O has 1.4x higher incidence]
        Acute Renal Failure - 8.5% O, 4.3% Epo [O has 2x higher incidence]
        Convulsions - 1.2% O, 0.3% [O has 4x higher incidence]
        Treatment Failure - 3.5% O, 1.5% Epo [O has 2.3x higher incidence]

        IMHO Maxdad is a key player in what I call Operation AFFY Retail Bagholders. Remember retail can only buy and sell AFFY and cannot short AFFY. Play the MM price swing and the pump and dump, but do not hold AFFY overnight and especially do not buy and hold AFFY to become an AFFY Bagholder. AFFY is severely financially and economically distressed such that it can declare bankruptcy at any time. There is very high risk in owning AFFY stock.

 
AFFY
0.1015+0.0005(+0.50%)Jul 22 3:19 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.